2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PLGA: From a classic drug carrier to a novel therapeutic activity contributor.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Poly(lactic-co-glycolic acid) (PLGA) is well known for its biocompatibility and minimal toxicity. It is one of the most promising biodegradable polymeric drug delivery systems able to get endorsement from regulatory bodies to enter market. For many decades, PLGA has been functioning as an excipient, which by definition is pharmaceutically inert at a given dose of formulation. Lactate (one of the hydrolysis products of PLGA) has a key role in biochemical pathways and could improve physiological activities in certain illnesses by exerting therapeutic effects such as angiogenesis and promotion of healing. These activities, however, depend on the released amounts and metabolic clearance of lactate and route of formulation delivery. In the current commentary, along with several key notes on the lactate interactions, we would like to inform the PLGA research community that lactate (resulting from local delivery of physiologically significant amount of PLGA) may positively or negatively affect therapeutic efficacy of certain drugs. Hence, the excipient role of PLGA may be investigated for its potential pharmacological contributions in some biomedical applications.

          Related collections

          Author and article information

          Journal
          J Control Release
          Journal of controlled release : official journal of the Controlled Release Society
          Elsevier BV
          1873-4995
          0168-3659
          November 10 2018
          : 289
          Affiliations
          [1 ] Novartis Pharma AG, Postfach 4002, Basel, Switzerland. Electronic address: kiran.chereddy@novartis.com.
          [2 ] Pole of Pediatric Hepatology, Institute of Clinical and Experimental Research (IREC), Université catholique de Louvain, Brussels, Belgium; Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium.
          [3 ] Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. Electronic address: veronique.preat@uclouvain.be.
          Article
          S0168-3659(18)30546-7
          10.1016/j.jconrel.2018.09.017
          30244137

          Comments

          Comment on this article